Boston Scientific Corporation BSX

NYSE · Healthcare · Medical - Devices

$41.98

Close on Fri, 20 Nov 2026 · market value $60.8B

What the price is betting on

Below its record

At $42, the price assumes revenue grows about 0.6% a year for five years, from $21.1B to about $21.6B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes0.6%
Analysts, next two years1.2%
Last 3 years15%

Revenue growth a year. The price figure comes from a reverse DCF at a 7.6% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than BSX? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$21.1B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$42

Base

$48

Bull

$53

Today $42

  • Bear $42. Cash flow grows 1% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $48. Cash flow grows 3% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $53. Cash flow grows 5% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$21.1B$21B, on the path
  3. FY2027$21.2B$20.8B, on the path
  4. FY2028$21.4B$21.9B, on the path
  5. FY2029$21.5B$23.2B, on the path
  6. FY2030$21.6B$25.6B, on the path

Each year's revenue at 0.6% growth from $21.1B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Devices · listed on NYSE

Revenue, FY2025
$20.1B
Growth, 3 years a year
15%
Cash margin
18%
Net debt
$10.4B
Shares, 3-year change
+3.8%
Dividend yield
0%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.